Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering Plough says bipolar drug has potential

Schering Plough says bipolar drug has potential

9th May 2008

Trial data seems to support the potential of asenapine as an effective drug to manage the symptoms of bipolar I disorder and schizophrenia, Schering-Plough (SP) says.

It announced its findings of two short-term bipolar mania studies and two schizophrenia studies at the 161st annual meeting of the American Psychiatric Association.

Asenapine is a fast-dissolving, novel psychopharmacologic agent with a unique human receptor signature and was acquired by SP at the end of last year from its developer, Organon BioSciences.

The findings were welcomed by Roger McIntyre, associate professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto.

“New therapies that are both effective and well-tolerated would be welcome additions to the treatment options currently available for improving patient care,” he said.

Bipolar disorder is described by the National Institute of Mental Health as being characterised by severe shifts in moods and energy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.